Related Experiment Video
Updated: Mar 6, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Viruses: Treatment and Implications for Patients With Gliomas
1University of Texas MD Anderson Cancer Center.
Background:
Oncolytic viral therapies are increasingly being explored for the treatment of diverse cancer types, most notably melanoma. However, advances in the treatment of high-grade gliomas, and specifically glioblastoma multiforme (GBM), are the result of novel oncolytic viral therapies. Delta-24-RGD is one such therapy that has demonstrated promising results in phase 1 trials. .
Objectives:
The objective of this article is to provide an overview of Delta-24-RGD, highlighting considerations for nurses in diverse clinical, research, and advanced practice roles. .
Methods:
A high-level overview of the pathophysiology of the Delta-24-RGD virus as it relates to GBM is presented. A case study is used to illustrate the course of care for a patient receiving this therapy. .
Findings:
Delta-24-RGD has demonstrated remarkable clinical efficacy in the near to complete regression of GBM activity. Nurses may increasingly be caring for patients who are undergoing such therapy or have received it in the past. Understanding the mechanism of action, safe-handling implications, and expected patient care needs and treatment sequelae is important.
Insights
Delta-24-RGD, an oncolytic virus therapy, shows significant promise in treating glioblastoma multiforme (GBM). This novel approach offers potential for near-complete regression of GBM, benefiting patients and guiding nursing care.
Area of Science:
- Oncolytic virotherapy
- Viral oncology
- Neuro-oncology
Background:
- Oncolytic viral therapies are emerging as a significant treatment modality for various cancers.
- High-grade gliomas, particularly glioblastoma multiforme (GBM), are seeing advancements through novel oncolytic viral agents.
- Delta-24-RGD is a promising oncolytic virus therapy that has shown positive outcomes in early-phase clinical trials.
Observation:
- This article provides an overview of the Delta-24-RGD oncolytic virus.
- It highlights key considerations for nurses across clinical, research, and advanced practice settings.
- The pathophysiology of Delta-24-RGD in relation to GBM is discussed, supported by a patient case study.
Findings:
- Delta-24-RGD demonstrates significant clinical efficacy, leading to substantial regression of GBM.
- Nurses will increasingly encounter patients receiving or having received Delta-24-RGD therapy.
- Understanding the virus's mechanism, safe handling, patient care needs, and treatment side effects is crucial.
Implications:
- This therapy offers a new avenue for glioblastoma treatment.
- Educating healthcare professionals, especially nurses, is vital for effective patient management.
- Further research and clinical application of Delta-24-RGD are warranted.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...